Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 11/20 | 0.53 |
| ▸ | PIM2 | Q9P1W9 | 10/20 | 0.53 |
| ▸ | IGF1R | P08069 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | TTR | P02766 | 1/20 | 0.43 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.43 |
| ▸ | NAT1 | P18440 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27000140 | 0.83 | PIM1 (0.50) | PIM1PIM2IGF1RHPGDPIM3 | |
| SCHEMBL3804713 | 0.80 | PIM1 (0.47) | PIM1PIM2IGF1RHPGDPIM3 | |
| SCHEMBL6594912 | 0.80 | PIM1 (0.47) | PIM1PIM2IGF1RHPGDPIM3 | |
| SCHEMBL6594906 | 0.80 | PIM1 (0.47) | PIM1PIM2IGF1RHPGDPIM3 | |
| SCHEMBL18163760 | 0.79 | MYC (0.53) | HPGDRAB9ANPC1TDP1NAT1 | |
| SCHEMBL18232390 | 0.79 | POLB (0.45) | PIM1PIM2IGF1RGSK3B | |
| SCHEMBL679542 | 0.79 | PIM1 (0.46) | PIM1PIM2IGF1RHPGDPIM3 | |
| SCHEMBL679543 | 0.79 | PIM1 (0.46) | PIM1PIM2IGF1RHPGDPIM3 | |
| SCHEMBL679788 | 0.77 | PIM1 (0.45) | PIM1PIM2IGF1RHPGDPIM3 | |
| SCHEMBL678088 | 0.77 | PIM1 (0.45) | PIM1PIM2IGF1RHPGDPIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021097326-A1 | ARYL AMINOPYRIMIDINES AS DUAL MERTK AND TYRO3 INHIBITORS AND METHODS THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2021-05-20 | — | — | WO | disclosed |
| US-20120149701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2012-06-14 | — | — | US | disclosed |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS, INC. | 2012-03-08 | — | — | US | disclosed |
| US-20110046165-A1 | CERTAIN CHEMICAL ENTITLES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2011-02-24 | — | — | US | disclosed |
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE | 2009-12-17 | — | — | US | disclosed |
| US-7524837-B2 | Benzotriazapinone salts and methods for using same | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-28 | — | — | US | disclosed |
| US-20070185093-A1 | Benzotriazepine derivatives and their use as gastrin and cholecystokinin receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312319-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | PIM1 257/4885PIM2 258/4885IGF1R 975/4885 |
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | MAP3K13, AKT3, PIK3CA | PIM1 560/4885PIM2 694/4885IGF1R 1083/4885 |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | PIM1 475/4885PIM2 513/4885IGF1R 902/4885 |
| US-20070185093-A1 | Benzotriazepine derivatives and their use as gastrin and cholecystokinin receptor ligands | CCKBR, GRPR, CCKAR | PIM1 4293/4885PIM2 4355/4885IGF1R 558/4885 |
| US-20120149701-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | PIM1 393/4885PIM2 489/4885IGF1R 1007/4885 |
| US-20110046165-A1 | CERTAIN CHEMICAL ENTITLES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | PIM1 903/4885PIM2 1175/4885IGF1R 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.